4.1. Known Candidate Predictive Markers of the Efficacy of Single-Agent ICI and Combined Immunotherapies for HCC: PD-L1 Expression, Tumor Mutation Burden (TMB), and Microsatellite Instability (MSI). The gene discussed is CD274; the disease is hepatocellular carcinoma.